Image

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market – Industry Trends and Forecast to 2029

Pharmaceutical

Image

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market – Industry Trends and Forecast to 2029

  • Pharmaceutical
  • Upcoming Report
  • Jun 2022
  • Global
  • 350 Pages
  • No of Tables: 220
  • No of Figures: 60

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market – Industry Trends and Forecast to 2029

Market Size in USD Billion

CAGR :  % Diagram

Diagram Forecast Period 2021–2029
Diagram Market Size (Base Year) USD 405.90 USD Million
Diagram Market Size (Forecast Year) USD 651.84 USD Million
Diagram CAGR %

Major Markets Players

  • Dummy1
  • Dummy2
  • Dummy3
  • Dummy4
  • Dummy5

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, By Type (Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder without Aquaporin-4 Antibodies), Treatment Type (Medication, Plasma Exchange Therapy, Immunoglobulin Therapy), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), Diagnosis (Imaging Tests, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others) – Industry Trends and Forecast to 2029

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market

Market Analysis and Size

Neuromyelitis optica spectrum disorder (NMOSD) is a chronic brain and spinal cord ailment characterized by inflammation of the optic nerve (optic neuritis) and spinal cord inflammation (myelitis). It was once thought to be a monophasic condition, with periods of inflammation of one or both optic nerves and the spinal cord lasting only a few days or weeks and no recurrence beyond the initial episode. According to new research, most individuals who meet the existing criteria for NMOSD have many attacks separated by periods of remission. This condition is also termed as Devic disease.

Data Bridge Market Research analyses that the neuromyelitis optica spectrum disorder (NMOSD) market was valued at USD 405.9 million in 2021 and is expected to reach USD 651.84 million by 2029, registering a CAGR of 6.10% during the forecast period of 2022 to 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Report Scope and Market Segmentation

Report Metric

Details

Forecast Period

2022 to 2029

Base Year

2021

Historic Years

2020 (Customizable to 2014 - 2019)

Quantitative Units

Revenue in USD Million, Volumes in Units, Pricing in USD

Segments Covered

Type (Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies, Neuromyelitis Optica Spectrum Disorder without Aquaporin-4 Antibodies), Treatment Type (Medication, Plasma Exchange Therapy, Immunoglobulin Therapy), Route of Administration (Oral, Parenteral, Others), Dosage Form (Tablets, Injections, Others), Diagnosis (Imaging Tests, Blood Tests, Others), End-Users (Hospitals, Specialty Clinics, Homecare, Others), Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Others)

Countries Covered

U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

Market Players Covered

F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GlaxoSmithKline plc (U.K.), Novartis AG (Switzerland), Zydus Cadila (India), Boehringer Ingelheim International GmbH. (Germany), Apotex Inc. (Canada), AstraZeneca (U.K.), Horizon Therapeutics PLC (Ireland), Johnson & Johnson Private Limited (U.S.), Bayer AG (Germany), Sun Pharmaceutical Industries Ltd. (India), LEO Pharma A/S (Denmark), Bausch Health Companies Inc. (Canada), Allergan (Ireland), Eli Lilly and Company (U.S.), Aurobindo Pharma (India), Lupin (India)

Market Opportunities

  • Increase in the number of research and development activities
  • Launch of new product and therapies

Market Definition

NMOSD (neuromyelitis optica spectrum disorder) is a central nervous system inflammatory ailment that was previously known as Devic disease or neuromyelitis optica (NMO). It's a devastating, life-long disease marked by spinal cord inflammation and optic nerve. Paralysis, muscle weakness, and blindness are common neuromyelitis optica spectrum disease symptoms. Non-Caucasian women are more likely to have neuromyelitis optica spectrum disorder. Genentech's Satralizumab is currently through a phase III clinical trial. It's a humanized monoclonal antibody that targets the IL-6 receptor in clinical trials. It's being tested to examine whether it can help with neuromyelitis optica spectrum disorder (NMOSD).

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Dynamics

Drivers

  • Increasing investment for healthcare infrastructure

Another significant factor influencing the growth rate of neuromyelitis optica spectrum disorder (NMOSD) market is the rising healthcare expenditure which helps in improving its infrastructure. Along with this, for better patient outcomes, manufacturers in the market for treating optic nerve disorders are teaching healthcare professionals about drug-specific factors of topical ocular corticosteroids, such as AE profile, potency, and patient-specific administration needs. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

  • High prevalence of multiple sclerosis (MS)

The high prevalence of multiple sclerosis is expected to act as a major driver for neuromyelitis optica spectrum disorder (NMOSD) market's growth. MS is an autoimmune disease in which the immune system assaults healthy bodily components, resulting in eyesight loss or decrease in more than half of the cases. As a result, manufacturers are expanding their production capacity in order to develop immunosuppressive medications that improve patients' quality of life. In September 2019, Roche, a Swiss multinational healthcare company, announced the results of clinical studies for Ocrevus, an immunosuppressive medicine, to better understand its impact in relapsing and progressive MS.

Furthermore, rising initiatives by public and private organizations to spread awareness and surging geriatric population will expand the neuromyelitis optica spectrum disorder (NMOSD) market. Additionally, high incidence of neuromyelitis optica spectrum disorder (NMOSD) and the sedentary lifestyle of people will result in the expansion of neuromyelitis optica spectrum disorder (NMOSD) market.

Opportunities

  • Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities of medication for symptomatic treatment of osteoarthritis. This will provide beneficial opportunities for market growth for neuromyelitis optica spectrum disorder (NMOSD). The pivotal phase III study of the experimental medication satralizumab for the treatment of neuromyelitis optica spectrum condition was announced by F. Hoffmann-La Roche Ltd in December 2019. The phase III clinical trial for neuromyelitis optica spectrum condition with inebilizumab (Anti-CD19 mAb) was finished in 2019. Viela Bio is the provider.

  • Launch of new products and therapies

The increasing number of new product launches and therapies for the treatment of the neuromyelitis optica spectrum disorder (NMOSD) is anticipated to create new market opportunities during the forecast period of 2022 to 2029. The advent of new therapies for the treatment of neuromyelitis optica spectrum syndrome poses a potential market opportunity. Bevacizumab and Alpha1-antitrypsin and Rituximab and Eculizumab are two new treatments in progression for the acute phase and prophylaxis, respectively.

Moreover, rising investment for the development of advanced technologies and increase in the number of emerging markets will further provide beneficial opportunities for the neuromyelitis optica spectrum disorder (NMOSD) market growth during the forecast period.

Restraints/Challenges

On the other hand, high cost associated with the treatment will obstruct the growth rate of market. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the neuromyelitis optica spectrum disorder (NMOSD) market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This neuromyelitis optica spectrum disorder (NMOSD) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the neuromyelitis optica spectrum disorder (NMOSD) market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

The prevalence of NMOSD is comparable over the world, rarely exceeding 5 per 100,000. 4 The proportion of MS and NMOSD patients is more a function of MS prevalence variability than NMOSD prevalence variability. Females suffer more than males (3:1 in MS vs. 9:1 in NMOSD). The median age at presentation is 39 years, however children and the elderly account for 18% of cases. It is generally thought to be a non-familial disorder.

Neuromyelitis optica spectrum disorder (NMOSD) market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Recent Development

  • In August 2020, the U.S. Food and Drug Administration (FDA) had approved Enspryng (satralizumab-mwge) for treating neuromyelitis optica spectrum disorder (NMOSD) in adults. Enspryng was given fast track designation, which expedites the development and review of drugs that are intended to treat a serious condition and show promise of meeting an unmet medical need. The drug was also designated as an orphan drug, which provides financial incentives to help and stimulate drug development for rare disorders.

Global Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Scope

The neuromyelitis optica spectrum disorder (NMOSD) market is segmented on the basis of type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Type

  • Neuromyelitis Optica Spectrum Disorder with Aquaporin-4 Antibodies
  • Neuromyelitis Optica Spectrum Disorder without Aquaporin-4 Antibodies

Treatment Type

  • Medication
  • Immunosuppressive Agent
  • C5 Protein Inhibitor
  • Monoclonal Antibodies
  • Corticosteroids
  • Others
  • Plasma Exchange Therapy
  • Immunoglobulin Therapy
  • Diagnosis
  • Imaging Tests
  • Magnetic resonance imaging (MRI)
  • Others
  • Blood Tests
  • Others

Dosage form

  • Tablets
  • Injections
  • Others

Route of Administration

  • Oral
  • Parenteral
  • Others

End-Users

  • Hospitals
  • Specialty Clinics
  • Homecare
  • Others

Distribution Channel

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy
  • Others

Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Regional Analysis/Insights

The neuromyelitis optica spectrum disorder (NMOSD) market is analysed and market size insights and trends are provided by country, type, treatment type, diagnosis, dosage form, route of administration, end-users and distribution channel as referenced above.

The countries covered in the neuromyelitis optica spectrum disorder (NMOSD) market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the neuromyelitis optica spectrum disorder (NMOSD) market because of the launch of new treatment options in this region. Additionally, rising healthcare expenditure along with the availability of treatment options will further propel the market's growth rate in this region.

Asia-Pacific is expected to grow during the forecast period due to presence of generic manufacturers in this region. Also, development of healthcare infrastructure and rising geriatric population will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Neuromyelitis Optica Spectrum Disorder (NMOSD) Market Share Analysis

The Neuromyelitis optica spectrum disorder (NMOSD) market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to neuromyelitis optica spectrum disorder (NMOSD) market.

Some of the major players operating in the neuromyelitis optica spectrum disorder (NMOSD) market are:

  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • Mylan N.V. (U.S.)
  • Teva Pharmaceutical Industries Ltd.(Israel)
  • Sanofi (France), Pfizer Inc. (U.S.)
  • GlaxoSmithKline plc (U.K.)
  • Novartis AG (Switzerland)
  • Zydus Cadila (India)
  • Boehringer Ingelheim International GmbH. (Germany)
  • Apotex Inc. (Canada)
  • AstraZeneca (U.K.)
  • Horizon Therapeutics PLC (Ireland)
  • Johnson & Johnson Private Limited (U.S.)
  • Bayer AG (Germany)
  • Sun Pharmaceutical Industries Ltd. (India)
  • LEO Pharma A/S (Denmark)
  • Bausch Health Companies Inc. (Canada)
  • Allergan (Ireland)
  • Eli Lilly and Company (U.S.)
  • Aurobindo Pharma (India)
  • Lupin (India)


SKU-

Please fill in the below form for detailed Table of Content

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Table

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for detailed List of Figure

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Please fill in the below form for Infographics

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Research Methodology:

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Please fill in the below form for Research Methodology

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Customization Available:

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Please fill in the below form for Available Customization

By clicking the "Submit" button, you are agreeing to the Data Bridge Market Research Privacy Policy and Terms and Conditions

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking
Request for Demo

FREQUENTLY ASK QUESTIONS

The market value for neuromyelitis optica spectrum disorder (NMOSD) market is expected USD 651.84 million by 2029.
The Neuromyelitis Optica Spectrum Disorder (NMOSD) Market is to grow at a CAGR of 6.10% during the forecast by 2029.
The significant factors flourishing the growth of the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market are Increasing investment for healthcare infrastructure, and High prevalence of multiple sclerosis (MS).
The major countries covered in the Neuromyelitis Optica Spectrum Disorder (NMOSD) Market are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Free Sample Report

CHOOSE LICENCE TYPE

  • 7000.00
  • 4800.00
  • 3000.00
  • 8000.00
  • 12000.00

Why Choose Us

Industry Coverage

DBMR works across the globe in multiple industries which equip us with knowledge across verticals and provide our clients with insights not only from their industry but how other industries will impact their ecosystem.

Regional Coverage

Coverage of Data Bridge is not restricted to developed or emerging economies. We work across the globe covering the largest array of countries where no other market research or business consulting firm has ever conducted research; creating growth opportunities for our clients in areas which are still unknown.

Technology Coverage

In today’s world, technology drives the market sentiment, so our vision is to provide our clients insights not only for developed technologies but upcoming and disrupting technological changes throughout the product lifecycle by enabling them with unforeseen opportunities in the market which will create disruption in their industry. This leads to innovation and our clients to come out as winners.

Goal Oriented Solutions

DBMR goal is to help our clients achieve their goals through our solutions; hence we formatively create the most appropriate solutions for our client needs, saving time and efforts for them to drive their grand strategies.

Unparallel Analyst Support

Our analysts take pride in our clients’ success. Unlike others, we believe in working along our clients to achieve their goals with 24 hours analyst support determining the correct needs and inspire innovation through service.

Banner

Client Testimonials